These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37145594)

  • 1. Buprenorphine Utilization and Prescribing Among New Jersey Medicaid Beneficiaries After Adoption of Initiatives Designed to Improve Treatment Access.
    Treitler P; Nowels M; Samples H; Crystal S
    JAMA Netw Open; 2023 May; 6(5):e2312030. PubMed ID: 37145594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine Prescribing and Challenges Faced Among National Health Service Corps Clinicians.
    Rowan K; Shah SV; Binns S; Murphy E; Satorius J; Ghobadi A; Krauss D; Robbins C; Schoebel V; Knudson A; Kepley H;
    JAMA Netw Open; 2024 May; 7(5):e2411742. PubMed ID: 38758556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs.
    Keshwani S; Maguire M; Goodin A; Lo-Ciganic WH; Wilson DL; Hincapie-Castillo JM
    JAMA Health Forum; 2022 Jun; 3(6):e221757. PubMed ID: 35977240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are North Carolina clinicians delivering opioid use disorder treatment to Medicaid beneficiaries?
    Grove LR; Rao N; Domino ME
    Addiction; 2022 Nov; 117(11):2855-2863. PubMed ID: 35194878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trends in Methadone Dispensing for Opioid Use Disorder After Medicare Payment Policy Changes.
    Taylor EA; Cantor JH; Bradford AC; Simon K; Stein BD
    JAMA Netw Open; 2023 May; 6(5):e2314328. PubMed ID: 37204793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Removal of Medicaid Prior Authorization Requirements and Buprenorphine Treatment for Opioid Use Disorder.
    Christine PJ; Larochelle MR; Lin LA; McBride J; Tipirneni R
    JAMA Health Forum; 2023 Oct; 4(10):e233549. PubMed ID: 37862034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid use disorder treatment and the role of New Jersey Medicaid policy changes: perspectives of office-based buprenorphine providers.
    Mahone A; Enich M; Treitler P; Lloyd J; Crystal S
    Am J Drug Alcohol Abuse; 2023 Sep; 49(5):606-617. PubMed ID: 37506336
    [No Abstract]   [Full Text] [Related]  

  • 8. Buprenorphine prescribing for opioid use disorder in medical practices: can office-based out-patient care address the opiate crisis in the United States?
    Rhee TG; Rosenheck RA
    Addiction; 2019 Nov; 114(11):1992-1999. PubMed ID: 31307111
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Composition of buprenorphine prescribing networks in Medicaid and association with quality of care.
    Zhu JM; Charlesworth CJ; Stein BD; Drake C; Polsky D; Korthuis PT; McConnell KJ
    J Subst Use Addict Treat; 2024 Aug; 163():209363. PubMed ID: 38641055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Buprenorphine-Waivered Physician Supply With Buprenorphine Treatment Use and Prescription Opioid Use in Medicaid Enrollees.
    Wen H; Hockenberry JM; Pollack HA
    JAMA Netw Open; 2018 Sep; 1(5):e182943. PubMed ID: 30646185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association Between Hospital Adoption of an Emergency Department Treatment Pathway for Opioid Use Disorder and Patient Initiation of Buprenorphine After Discharge.
    Solomon KT; O'Connor J; Gibbons JB; Kilaru AS; Feder KA; Xue L; Saloner B; Stuart EA; Cole ES; Hulsey E; Meisel Z; Patel E; Donohue JM
    JAMA Health Forum; 2023 Mar; 4(3):e230245. PubMed ID: 36961457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implementation of an office-based addiction treatment model for Medicaid enrollees: A mixed methods study.
    Treitler P; Enich M; Bowden C; Mahone A; Lloyd J; Crystal S
    J Subst Use Addict Treat; 2024 Jan; 156():209212. PubMed ID: 37935350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growing importance of high-volume buprenorphine prescribers in OUD treatment: 2009-2018.
    Schuler MS; Dick AW; Gordon AJ; Saloner B; Kerber R; Stein BD
    Drug Alcohol Depend; 2024 Jun; 259():111290. PubMed ID: 38678682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Selected State Policies and Requirements for Buprenorphine Treatment With Per Capita Months of Treatment.
    Stein BD; Saloner BK; Golan OK; Andraka-Christou B; Andrews CM; Dick AW; Davis CS; Sheng F; Gordon AJ
    JAMA Health Forum; 2023 May; 4(5):e231102. PubMed ID: 37234015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.
    Miles J; Treitler P; Hermida R; Nyaku AN; Simon K; Gupta S; Crystal S; Samples H
    Drug Alcohol Depend; 2023 Nov; 252():110963. PubMed ID: 37748421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics of Office-Based Buprenorphine Prescribers for Medicare Patients.
    Abraham R; Wilkinson E; Jabbarpour Y; Petterson S; Bazemore A
    J Am Board Fam Med; 2020; 33(1):9-16. PubMed ID: 31907241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program.
    Nyaku AN; Zerbo EA; Chen C; Milano N; Johnston B; Chadwick R; Marcello S; Baston K; Haroz R; Crystal S
    BMC Health Serv Res; 2024 Feb; 24(1):179. PubMed ID: 38331802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Racial and Ethnic Disparities in Buprenorphine and Extended-Release Naltrexone Filled Prescriptions During the COVID-19 Pandemic.
    Nguyen T; Ziedan E; Simon K; Miles J; Crystal S; Samples H; Gupta S
    JAMA Netw Open; 2022 Jun; 5(6):e2214765. PubMed ID: 35648400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.